# AIM ImmunoTech Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/AIM ImmunoTech Inc.).

## Overview

AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. Its pipeline centers on Ampligen® (rintatolimod), a nucleic-acid based immune modulator studied across indications including ME/CFS and immuno-oncology, and it also has an FDA-approved interferon product, Alferon N Injection. The company’s commercialization approach relies heavily on partnering—licensing, collaborations, and potential joint ventures—to obtain regulatory approvals and build commercial reach in specific territories. AIM currently generates only limited revenue (e.g., via an Ampligen cost recovery program) and positions partnerships and external funding as key enablers of development and commercialization.

## Products & services

• Ampligen® (rintatolimod) development for ME/CFS and oncology
• Ampligen® Cost Recovery Program (patient access)
• Alferon N Injection (natural interferon; FDA-approved)
• Out-licensing / co-development partnerships by territory
• Clinical/regulatory support activities (CRO-led trial execution)

- **Ampligen® (rintatolimod) pipeline** (70%) — R&D and clinical development of Ampligen across ME/CFS, oncology and viral-disease applications.
- **Partnering and licensing arrangements** (15%) — Territory-based licensing/collaboration/joint-venture efforts to obtain approvals and commercialize products.
- **Ampligen Cost Recovery / expanded access supply** (10%) — Limited patient access programs where participants support costs, producing small, variable revenue.
- **Alferon N Injection** (5%) — FDA-approved natural interferon product with commercialization dependent on partners and market access.

- Ampligen® (rintatolimod) development for ME/CFS and oncology
- Ampligen® Cost Recovery Program (patient access)
- Alferon N Injection (natural interferon; FDA-approved)
- Out-licensing / co-development partnerships by territory
- Clinical/regulatory support activities (CRO-led trial execution)

## Customers

AIM’s near-term customers are a mix of (1) patients and clinical sites participating in access programs that support the cost of Ampligen supply, and (2) research institutions receiving product for antiviral research. A second, strategically critical “customer” group is potential pharmaceutical partners that can fund development, run registration programs, and commercialize Ampligen in specific territories. In Argentina, the company has worked through a distributor/partner model (GP Pharm/Filaxis) aimed at regulatory approval and commercialization for severe CFS, with exploration of oncology use cases such as pancreatic cancer. Because AIM does not currently generate material operating revenues, partner selection and deal terms (milestones, supply, territory rights) are central to how demand ultimately converts into revenue.

- **Biopharma licensing and co-development partners** (primary) — License or co-develop Ampligen (and potentially Alferon) to fund trials, secure approvals, and commercialize in defined territories.
- **Patients and providers in cost recovery / expanded access** (secondary) — Access Ampligen for severe disease settings (e.g., ME/CFS) with participation levels driving small, fluctuating revenue.
- **Academic and government-affiliated research labs** (emerging) — Obtain Ampligen supply for preclinical/clinical research (e.g., antiviral studies) to generate data supporting future development.
- **Regional commercialization partners (Latin America)** (emerging) — Distribute and commercialize Ampligen locally (historically Argentina via GP Pharm/Filaxis) subject to regulatory approvals and contract renewals.

- Patients in Ampligen cost recovery/expanded access programs seeking treatment
- Hospitals/clinics administering Ampligen under access protocols
- Pharma partners licensing Ampligen for local approvals and commercialization
- Regional distributors in Latin America (e.g., Argentina-focused partner model)
- Research institutions using Ampligen in antiviral studies (e.g., SARS-CoV-2)

## Geography

AIM is headquartered in Ocala, Florida and operates primarily as a U.S.-based R&D organization while pursuing international commercialization through territorial partners. The most explicit non-U.S. commercial footprint discussed is Argentina, where a partner (GP Pharm/Filaxis) has been responsible for regulatory approval and commercialization efforts for Ampligen in severe CFS, with local regulatory authorization extended through 2026. The company also references a strategy to make Ampligen available worldwide via licensing/collaborations/joint ventures, implying a partner-led expansion model rather than building its own global sales infrastructure. Geography matters mainly through regulatory pathways, partner execution in each territory, and the ability to secure manufacturing and supply arrangements that can serve multiple regions.

- Headquarters and core operations in Ocala, Florida (U.S.)
- Argentina is a key partner-led market for Ampligen (ANMAT extension to 2026)
- Latin America expansion contemplated via partner milestone-based rights
- Global availability strategy relies on territory licensing/collaborations
- U.S. research collaborations support antiviral and oncology data generation

## Strategy

AIM’s strategy emphasizes finding senior co-development partners with the capital and expertise to run clinical programs, obtain regulatory approvals, and commercialize Ampligen across multiple indications and geographies. The company has used a partner/distributor model in Argentina and indicates openness to extending or replacing that partner to maintain momentum and broaden indications (including oncology such as pancreatic cancer). AIM also seeks to strengthen its intellectual property and manufacturing readiness for Ampligen, including patent filings related to coronavirus applications and a high-volume manufacturing process, and it has engaged external parties for clinical and regulatory support (e.g., a CRO). Corporate actions such as the 100-to-1 reverse stock split were undertaken to regain NYSE American compliance, supporting continued access to capital markets, which management indicates is necessary given limited operating revenue.

- **Partner-led development and commercialization of Ampligen** (short-term) — AIM indicates it lacks adequate funds to independently fund trials and commercialization.
- **Sustain and expand Latin America access via Argentina partnerships** (short-term) — Argentina is a concrete example of partner-led regulatory/commercial execution and could extend to other countries.
- **Broaden Ampligen evidence base in oncology and viral diseases** (medium-term) — Clinical and preclinical data are key to attracting partners and enabling regulatory pathways in new indications.
- **Protect IP and improve manufacturing scalability for Ampligen** (medium-term) — Commercial viability depends on defensible IP and reliable, higher-volume supply capabilities.

- Secure senior co-development partners to fund trials and commercialization
- Use territory licensing/JVs to expand Ampligen availability worldwide
- Maintain/replace Argentina partner to preserve local market access
- Advance Ampligen into oncology and viral-disease applications
- Strengthen IP and manufacturing pathways for scalable Ampligen supply
- Maintain listing compliance to support financing flexibility

## Risks

AIM faces high development and financing risk because it reports no material operating revenues and states it does not have adequate funds to meet anticipated cash needs and fund current clinical trials. Clinical and regulatory risk is significant: Ampligen’s broader approvals depend on time-consuming preclinical and clinical work, and negative or inconclusive results can force additional studies and delays. The partner-led model introduces counterparty and execution risk, illustrated by the Argentina arrangement where Alferon efforts were discontinued by the partner and the company is negotiating an extension while also considering a new partner. Like other small biopharma companies, AIM is exposed to manufacturing/supply chain risk for specialized biologic production, IP protection risk, and market adoption risk if competing therapies or standards of care evolve faster than its development timelines.

- **Insufficient capital to fund operations and clinical trials** [critical] — The company states it does not have adequate funds to meet anticipated cash needs and does not generate material revenues.
- **Dependence on partners for territorial approvals and commercialization** [high] — Strategy relies on licensing/collaborations/JVs; partner priorities can change and agreements may not be renewed.
- **Revenue volatility from small cost recovery program participation** [medium] — Reported Ampligen cost recovery revenue fluctuates with patient participation and is not a stable commercial base.

- Funding shortfall risk due to limited operating revenues and ongoing R&D spend
- Clinical trial failure or delays can force additional studies and costs
- Regulatory approval uncertainty across indications and geographies
- Partner/distributor execution risk (renewals, milestones, strategic shifts)
- Manufacturing scale-up and outsourced supply risk for Ampligen components
- IP protection and patent prosecution risk for Ampligen-related filings
- Concentration risk from reliance on a small number of programs (Ampligen)

## Accounting

AIM’s reported revenue includes amounts from its Ampligen® Cost Recovery Program, where revenue can fluctuate based on patient participation and timing, making period-to-period comparisons noisy. As a development-stage biopharma with limited revenue, operating results are heavily influenced by the timing of R&D and G&A spending, including the start/stop cadence of clinical activities and outsourced services. The company’s results also reference non-operating items such as gains/losses on investments and warrant valuation impacts, which can create significant volatility in net income (loss) unrelated to core R&D progress. Investors should pay close attention to fair value measurement of warrants and investments, and to the classification and disclosure of any collaboration or licensing arrangements that could introduce milestone-based or variable consideration revenue recognition in future periods.

- **Revenue recognition for Ampligen Cost Recovery Program** — Quarterly revenue volatility and limited visibility into run-rate demand
- **Fair value accounting for warrants** — Material swings in other income/expense and net loss
- **Gains/losses on investments** — Non-operating volatility in reported results

- Cost recovery revenue timing and participation drives revenue volatility
- R&D expense timing depends on trial cadence and outsourced services
- Fair value changes in warrants can materially swing reported net loss
- Gains/losses on investments add non-operating earnings volatility
- Potential future milestone/license revenue may involve variable consideration

---

*Last updated: 2026-08-11T04:46:17.408587+00:00*